BTOG 2020 | Mesothelioma trials update: CONFIRM, BEAT-meso & MARS2

Sanjay Popat • 31 Jan 2020

Lung Cancer Mesothelioma Atezolizumab Bevacizumab Carboplatin Nivolumab Pemetrexed

BEAT-meso CONFIRM MARS2 PROMISE-meso Immuno-Oncology

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the various trials on mesothelioma. Prof. Popat highlights the CONFIRM (NCT03063450), BEAT-meso (NCT03762018) and MARS2 (NCT02040272) trial. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

Genomic testing for lung cancer in the UK

Sanjay Popat • 31 Jan 2022

KEYNOTE-407: pembrolizumab plus chemo improves OS and PFS in NSCLC

Sanjay Popat • 31 Mar 2021

ALTA-1L updates at ESMO 2020: intracranial efficacy and HRQoL

Sanjay Popat • 6 Oct 2020

Challenges and treatment of CNS metastases in NSCLC

Sanjay Popat • 19 Oct 2018

Related Videos

Building a clinical research platform to capture and leverage data from cancer care in Germany

Frank Griesinger • 6 Dec 2016

Improving responses to immunotherapy in NSCLC

Victor Moreno • 9 Nov 2018

How to discuss immunotherapy as a treatment option with lung cancer patients

Rolf Stahel • 29 Jan 2017

Clinical factors in the selection of patients for first-line immunotherapy of lung cancer

Benjamin Besse • 27 Jan 2017